HC Wainwright & Co. Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Neutral 54.2%

Neg 0% Neu 54.2% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $40.